Actavis, Noven Reach Deal Over Generic ADHD Patch Plans
Actavis PLC has reached a licensing deal with Noven Pharmaceuticals Inc. to make a generic version of Noven's attention deficit hyperactivity disorder treatment Daytrana, it announced Wednesday, ending patent litigation over...To view the full article, register now.
Already a subscriber? Click here to view full article